Thoms, J. A. I., Yan, F., Hampton, H. R., Davidson, S., Joshi, S., Saw, J., Sarowar, C. H., Lim, X. Y., Nunez, A. C., Kakadia, P. M., Bhuyan, G. S., Zou, X., Nguyen, M., Ghodousi, E. S., Koch, F. C., Vafaee, F., Thompson, I. R., Karimi, M. M., Pickford, R., Raftery, M. J., Hough, S., Buckland, G., Bailey, M., Ghodke, Y., Absar, N., Vaughan, L., Pasalic, L., Fong, C. Y., Kenealy, M., Hiwase, D. K., Stoddart, R. I., Mohammed, S., Lee, L., Passam, F. H., Larsen, S. R., Spring, K. J., Skarratt, K. K., Rebeiro, P., Presgrave, P., Stevenson, W. S., Ling, S., Tiley, C., Fuller, S. J., Roncolato, F., Enjeti, A. K., Hoenemann, D., Lemech, C., Jolly, C. J., Bohlander, S. K., Curtis, D. J., Wong, J. W. H., Unnikrishnan, A., Hertzberg, M., Olivier, J., Polizzotto, M. N., Pimanda, J. E. (2025). Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs. Nature Communications. https://doi.org/10.1038/s41467-025-59796-x